The V600E mutation in BRAF is a promising oncogene target for the anti-neoplastic drug dabrafenib; which was used in conjunction with a MEK inhibitor in a patient with stage 4 ameloblastoma with good results33. Here, MAP2K7 is linked to ameloblastoma.